Immune dysregulation and vascular risk in HIV-infected patients: Implications for clinical care

Journal of Infectious Diseases

Volumn 203, Issue 4, 2011, Pages 439-441

  Triant, Virginia A ^a   Grinspoon, Steven K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; CD57 ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE FLORA; MEDICAL EDUCATION; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; VIREMIA; VIRUS REPLICATION;

CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; INCIDENCE; RISK FACTORS;

EID: 79751472371     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq084     Document Type: Note

References (22)

1. Klein D, Hurley LB, Quesenberry CP Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-7.
2. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12. (Pubitemid 47037350)
3. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-49.
4. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-53.
5. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
6. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96. (Pubitemid 44837777)
7. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-87. (Pubitemid 351535369)
8. Kuller LH, Tracy R, Belloso W, et al. Inflammatory coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
9. Tien PC, Choi AI, Zolopa AR, et al. Inflammation mortality in HIV-Infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010. epub ahead of print.
10. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24:1897-905.
11. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women men. AIDS 2008; 22:1615-24.
12. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-47.
13. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and Virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010. epub ahead of print.
14. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-67.
15. Kaplan RC, Sinclair E, Landay AL, et al. T-cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2010; 203:452-63.
16. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
17. Panel on Antiretroviral Guidelines for Adults Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents., Washington: DC: Department of Health and Human Services 2009:1-161 http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 July 2010.
18. Antiretroviral therapy for HIV infection in adults adolescents: recommendations for a public health approach. 2010 revision. Geneva, Switzerland: World Health Organization, 2010:1-156 http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf. Accessed 7 October 2010.
19. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-33.
20. Hunt PW. Th17, gut, HIV: therapeutic implications. Curr Opin HIV AIDS 2010; 5:189-93.
21. Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med 2009; 24:334-40.
22. Tornero C, Ventura A, Mafe M. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 54:560.